Voxzogo

Chemical Namevosoritide
Dosage FormInjection (subcutaneous; 0.4 mg, 0.56 mg, 1.2 mg)
Drug ClassAnalogs
SystemMusculoskeletal
CompanyBioMarin
Approval Year2021

Indication

  • Indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Voxzogo (vosoritide) Prescribing Information.2021BioMarin Pharmaceutical Inc., Novato, CA
Document TitleYearSource
Assessment report: voxzogo.2021EMA